



Orchestrating Success in Oncology Nursing[®]

Puma Biotechnology to Sponsor

OCS 2023 Breakfast Product Theater

It's Time to Give NERLYNX a Second Look: A Case-Based Discussion on Reducing Recurrence in HER2+ eBC1-3 (and Patient Experience.)

7:00 am, Saturday, September 9, 2023, JW Marriott LA LIVE! (Platinum Ballroom)

presented by

Brian Leyland-Jones, MD, B Sc, MB BS, PhD (National Foundation for Cancer Research)



Title
Vice President, Molecular Experimental Medicine

Practice
Avera Cancer Institute Center for Precision Oncology and Department of Molecular and Experimental Medicine

Location
Sioux Falls, SD

Fellowship
The New York Hospital; Memorial Sloan-Kettering Cancer Center; Memorial Hospital, New York, NY

Biography
Dr. Brian Leyland-Jones, is the Chief Medical Officer and a Scientific Advisory Board member for the National Foundation for Cancer Research and is the Chief Scientific Officer of the Darwin Foundation. He sits on several national and international boards, including the Asian Foundation for Cancer Research (AFCR), NED Biosystems, Non-Pareil, and Ratio and is Director Emeritus of the WIN Consortium. He founded Xanthus, AKESOgen, and Vviphil.

Dr. Leyland-Jones holds biochemistry, medical, and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew's, and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in early-phase clinical development, clinical pharmacology, and biomarker evaluation of many anticancer compounds, including the platinum-containing agents and anthracycline analogs in use today.

He joined Emory University in 2007. As Director of the Winship Cancer Center and Associate Vice President of Health Sciences, Dr. Leyland-Jones led the Center to obtain National Cancer Institute Cancer Center Designation, the first in the State of Georgia, and for the first time in 30 years. Dr. Leyland-Jones was instrumental in building the Genomics Medicine Program at the Avera Cancer Institute in Sioux Falls, SD where he was the Vice President of Molecular and Experimental Medicine from 2014-2019.

Dr. Leyland-Jones is the recipient of numerous research grants and has served as principal investigator, co-principal investigator, and co-investigator on more than 100 clinical studies. He has authored and co-authored more than 210 peer-reviewed articles and book contributions, 25 books and book chapters, 425 abstracts, and 35 patents. He has a robust